SOURCE: NuPathe Inc.

NuPathe Inc.

March 14, 2011 08:00 ET

NuPathe to Report Fourth Quarter and Full Year 2010 Results and Hold Conference Call on Friday, March 18, 2010

CONSHOHOCKEN, PA--(Marketwire - March 14, 2011) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, will report fourth quarter and full year 2010 results on Friday, March 18, 2011 before the open of the U.S. financial markets. NuPathe will also host a conference call at 8:30 a.m. EDT on the same day to discuss the fourth quarter and full year 2010 financial results and recent operational highlights. A question and answer session will follow NuPathe's remarks.

To participate on the live call, please dial 877-397-0272 (domestic) or +1-719-325-4838 (international), and provide the participant passcode 6802591 five to ten minutes ahead of the start of the call. A replay of the call will be available for 90 days within a few hours after the call ends. Investors may listen to the replay of the call by dialing 888-203-1112 (domestic) or +1-719-457-0820 (international), with the passcode 6802591.

A live audio webcast of the call will be also available via the "Investor Relations" page of the NuPathe website, www.nupathe.com. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will be archived on NuPathe's website for 90 days following the call.

About NuPathe
NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, Zelrix™, is a single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.

Contact Information

  • Contact Information:

    John Woolford
    (443) 213-0506
    Email Contact

    Keith A. Goldan
    Vice President, Chief Financial Officer
    NuPathe Inc.
    (484) 567-0130